Ambrx Biopharma Inc Quick Ratio (AMAM) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ambrx Biopharma Inc   (NASDAQ: AMAM)

Ambrx Biopharma Inc 's Quick Ratio

AMAM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Ambrx Biopharma Inc 's Cash & cash equivalent, this led to improvement in Ambrx Biopharma Inc 's Quick Ratio to 12.33, above Ambrx Biopharma Inc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 35 other companies have achieved higher Quick Ratio than Ambrx Biopharma Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 266 to 275.

Explain Quick Ratio?
How much Cash & cash equivalents AMAM´s has?
What are AMAM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMAM Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Jun 30 2022)
Q3
Y / Y Current Liabilities Change 81.9 % 31.38 % -56.36 % -7.73 % -59.14 %
Y / Y Cash & cash equivalent Change 103.13 % 38.24 % -12.04 % -66.74 % -34.79 %
Quick Ratio MRQ 12.33 12.07 13.94 2.45 11.04
AMAM's Total Ranking # 275 # 266 # 378 # 729 #
Seq. Current Liabilities Change -6.18 % 81.52 % -52.7 % 125.81 % -32.24 %
Seq. Cash & cash equivalent Change -4.18 % 57.16 % 168.97 % -49.85 % -34.79 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 36
Healthcare Sector # 137
Overall Market # 275


Quick Ratio Statistics
High Average Low
12.93 8.48 5.07
(Jun 30 2023)   (Dec 31 2022)




Financial Statements
Ambrx Biopharma Inc 's Current Liabilities $ 18 Millions Visit AMAM's Balance sheet
Ambrx Biopharma Inc 's Cash & cash equivalent $ 225 Millions Visit AMAM's Balance sheet
Source of AMAM's Sales Visit AMAM's Sales by Geography


Cumulative Ambrx Biopharma Inc 's Quick Ratio

AMAM's Quick Ratio for the trailling 12 Months

AMAM Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -3.89 % -28.95 % -34.41 % 12.23 % 86.54 %
Y / Y Cash & cash equivalent TTM Growth 7.66 % -18.63 % -18.67 % 18.45 % 137.3 %
Quick Ratio TTM 9.35 8.76 8.34 7.02 8.35
Total Ranking TTM # 3263 # 3254 # 3437 # 3450 #
Seq. Current Liabilities TTM Growth 13.07 % 7.98 % -19.21 % -2.57 % -16.41 %
Seq. Cash & cash equivalent TTM Growth 20.75 % 13.38 % -4.04 % -18.05 % -8.74 %

Quick ratio ranking by company, industry and sector >> Back to AMAM Financial Strength Comparisons >> Go to Compare AMAM Quick Ratio to its Competitors

On the trailing twelve months basis AMAM Cash & cash equivalent more than doubled by 103.13 % in Q3 2023 year on year, faster than Current Liabilities, this led to increase in in Ambrx Biopharma Inc 's Quick Ratio to 9.35, above AMAM average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 170 other companies have achieved higher Quick Ratio than Ambrx Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3254 to 3263.

Explain Quick Ratio?
How much Cash & cash equivalents AMAM´s has?
What are AMAM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 171
Healthcare Sector # 1002
Within the Market # 3263


trailing twelve months Quick Ratio Statistics
High Average Low
10.15 7.18 3.76
(Sep 30 2023)   0




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Vaxcyte Inc   33.62 $ 1,265.684  Millions$ 37.650  Millions
Creative Medical Technology Holdings Inc   29.42 $ 11.974  Millions$ 0.407  Millions
Revolution Medicines Inc   27.45 $ 813.195  Millions$ 29.627  Millions
Quince Therapeutics Inc   27.34 $ 61.593  Millions$ 2.253  Millions
Apogee Therapeutics Inc   24.62 $ 422.854  Millions$ 17.178  Millions
Cullinan Therapeutics Inc   21.30 $ 466.430  Millions$ 21.897  Millions
Krystal Biotech Inc   20.38 $ 562.069  Millions$ 27.583  Millions
Prokidney Corp   19.51 $ 396.334  Millions$ 20.311  Millions
Tourmaline Bio Inc   19.49 $ 157.984  Millions$ 8.105  Millions
Lenz Therapeutics Inc   18.66 $ 233.986  Millions$ 12.537  Millions
Compass Therapeutics Inc   17.94 $ 163.703  Millions$ 9.124  Millions
4d Molecular Therapeutics Inc   17.60 $ 319.664  Millions$ 18.163  Millions
Icosavax Inc   17.59 $ 229.206  Millions$ 13.030  Millions
Neumora Therapeutics Inc   17.50 $ 509.565  Millions$ 29.123  Millions
Hillevax Inc   17.11 $ 324.410  Millions$ 18.958  Millions
Fusion Pharmaceuticals Inc   16.92 $ 191.348  Millions$ 11.312  Millions
Crispr Therapeutics Ag  15.64 $ 1,739.826  Millions$ 111.234  Millions
Denali Therapeutics Inc   15.58 $ 1,109.256  Millions$ 71.180  Millions
Engene Therapeutics Inc   15.51 $ 81.521  Millions$ 5.257  Millions
Cabaletta Bio Inc   15.49 $ 164.391  Millions$ 10.616  Millions
Voyager Therapeutics Inc   14.51 $ 252.936  Millions$ 17.427  Millions
Pharmacyte Biotech Inc   14.01 $ 73.425  Millions$ 5.240  Millions
Iteos Therapeutics Inc   13.82 $ 599.027  Millions$ 43.349  Millions
Caribou Biosciences Inc   13.78 $ 338.488  Millions$ 24.572  Millions
Vor Biopharma Inc   13.75 $ 160.098  Millions$ 11.645  Millions
Aura Biosciences Inc   13.68 $ 149.076  Millions$ 10.894  Millions
Vigil Neuroscience Inc   13.18 $ 133.643  Millions$ 10.142  Millions
Anavex Life Sciences Corp   13.00 $ 151.024  Millions$ 11.617  Millions
Replimune Group Inc   12.47 $ 496.761  Millions$ 39.832  Millions
Elevation Oncology inc   12.46 $ 94.797  Millions$ 7.607  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.